Hjem › Immunsystem og lidelser › Massachusetts
Immunsystem og lidelser kliniske forsøg i Massachusetts
10 studier for Immunsystem og lidelser søger deltagere på steder i Massachusetts.
Byer i Massachusetts
Officiel studietekst (engelsk)
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
- Beth Israel Deaconess Medical Center - Research, Boston
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 30. sep. 2026 · NCT07192471A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- Massachusetts General Hospital, Boston
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 18. sep. 2026 · NCT06722235Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects
- Brigham and Women's Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
RekruttererObservationsstudie
Alle aldre · Alle køn · Opdateret 17. sep. 2026 · NCT04242095(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
- Dana-Farber Cancer Institute, Boston
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 15. sep. 2026 · NCT04996875A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- Massachusetts General Hospital, Boston
- University of Massachusetts Chan Medical School, Worcester
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 9. sep. 2026 · NCT06948318A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
- Massachusetts General Hospital, Boston
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 28. aug. 2026 · NCT07075185A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- Massachusetts General Hospital, Boston
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 19. aug. 2026 · NCT04104776A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
- Brigham and Women's Hospital, Boston
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 29. maj 2026 · NCT04422912CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- Dana Farber Cancer Institute, Boston
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 16. apr. 2026 · NCT03328078A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
- Dana-Farber Cancer Institute, Boston
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 15. dec. 2025 · NCT06619561Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.